Mark Donnelly

Mark Donnelly

Auto-generated profile, based on publicly available information

Mark Donnelly

Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD 20993, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MDMark Donnelly
Mark Donnelly
LFLanyan Fang
Lanyan Fang
RMRajanikanth Madabushi
Rajanikanth Madabushi
HZHao Zhu
Hao Zhu
MLMarkham Luke
Markham Luke
LZLiang Zhao
Liang Zhao

23 August 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
XCXiaomei Chen
Xiaomei Chen
HNHenrik B. Nyberg
Henrik B. Nyberg
MDMark Donnelly
Mark Donnelly
LZLiang Zhao
Liang Zhao
LFLanyan Fang
Lanyan Fang
AHAndrew C. Hooker
Andrew C. Hooker
By applying nonlinear mixed‐effect (NLME) models, model‐integrated evidence (MIE) approaches are able to analyze bioequivalence (BE) data with pharmacokinetic end points that have sparse sampling, which is problematic for non‐compartmental analysis (NCA). However, MIE approaches may suffer from inflation of type I error due to underestimation of parameter uncertainty and to the assumption of asymptotic normality. In this study, we developed a MIE BE analysis method that is based on a pre‐defined model and consists of several steps including model fitting, uncertainty assessment, simulation, and BE determination. The presented MIE approach has several improvements compared with the previously reported model‐integrated methods: (1) treatment, sequence, and period effects are only added to absorption parameters (such as relative bioavailability and rate of absorption) instead of all PK parameters; (2) a simulation step is performed to generate confidence intervals of the pharmacokinetic metrics for BE assessment; and (3) in an effort to maintain type I error, two more advanced parameter uncertainty evaluation approaches are explored, a nonparametric (case resampling) bootstrap, and sampling importance resampling (SIR). To evaluate the developed method and compare the uncertainty assessment methods, simulation experiments were performed for BE studies using a two‐way crossover design with different amounts of information (sparse to rich designs) and levels of variability. Based on the simulation results, the method using SIR for parameter uncertainty quantification controls type I error at the nominal level of 0.05 (i.e., the significance level set for BE evaluation) even for studies with small sample size and/or sparse sampling. As expected, our MIE approach for BE assessment exhibited higher power than the NCA‐based method, especially as the data becomes sparser and/or more variable.

3 December 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MDMark Donnelly
Mark Donnelly
ETEleftheria Tsakalozou
Eleftheria Tsakalozou
SSSatish Sharan
Satish Sharan
TSThomas Straubinger
Thomas Straubinger
RBRobert Bies
Robert Bies
LZLiang Zhao
Liang Zhao
Click on the article title to read more.

27 April 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
CTCoralie Tardivon
Coralie Tardivon
FLFlorence Loingeville
Florence Loingeville
MDMark Donnelly
Mark Donnelly
KFKairui Feng
Kairui Feng
WSWanjie Sun
Wanjie Sun
JBJulie Bertrand
Julie Bertrand
In a traditional pharmacokinetic (PK) bioequivalence (BE) study, a two‐way crossover study is conducted, PK parameters (namely the area under the time‐concentration curve [AUC] and the maximal concentration []) are obtained by noncompartmental analysis (NCA), and the BE analysis is performed using the two one‐sided test (TOST) method. For ophthalmic drugs, however, only one sample of aqueous humor, in one eye, per eye can be obtained in each patient, which precludes the traditional BE analysis. To circumvent this issue, the U.S. Food and Drug Administration (FDA) has proposed an approach coupling NCA with either parametric or nonparametric bootstrap (NCA bootstrap). The model‐based TOST (MB‐TOST) has previously been proposed and evaluated successfully for various settings of sparse PK BE studies. In this paper, we evaluate, via simulations, MB‐TOST in the specific setting of single sample PK BE study and compare its performance to NCA bootstrap. We performed BE study simulations using a published PK model and parameter values and evaluated multiple scenarios, including study design (parallel or crossover), sampling times (5 or 10 spread across the dosing interval), and geometric mean ratio (of 0.8, 0.9, 1, and 1.25). Using the simulated structural PK model, MB‐TOST performed similarly to NCA bootstrap for AUC. For , the latter tended to be conservative and less powerful. Our research suggests that MB‐TOST may be considered as an alternative BE approach for single sample PK studies, provided that the PK model is correctly specified and the test drug has the same structural model as the reference drug.

28 August 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
HNHenrik Bjugård Nyberg
Henrik Bjugård Nyberg
XCXiaomei Chen
Xiaomei Chen
MDMark Donnelly
Mark Donnelly
LFLanyan Fang
Lanyan Fang
LZLiang Zhao
Liang Zhao
AHAndrew C. Hooker
Andrew C. Hooker
Conventional approaches for establishing bioequivalence (BE) between test and reference formulations using non‐compartmental analysis (NCA) may demonstrate low power in pharmacokinetic (PK) studies with sparse sampling. In this case, model‐integrated evidence (MIE) approaches for BE assessment have been shown to increase power, but may suffer from selection bias problems if models are built on the same data used for BE assessment. This work presents model averaging methods for BE evaluation and compares the power and type I error of these methods to conventional BE approaches for simulated studies of oral and ophthalmic formulations. Two model averaging methods were examined: bootstrap model selection and weight‐based model averaging with parameter uncertainty from three different sources, either from a sandwich covariance matrix, a bootstrap, or from sampling importance resampling (SIR). The proposed approaches increased power compared with conventional NCA‐based BE approaches, especially for the ophthalmic formulation scenarios, and were simultaneously able to adequately control type I error. In the rich sampling scenario considered for oral formulation, the weight‐based model averaging method with SIR uncertainty provided controlled type I error, that was closest to the target of 5%. In sparse‐sampling designs, especially the single sample ophthalmic scenarios, the type I error was best controlled by the bootstrap model selection method.

21 May 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ALAn Le
An Le
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
JZJunmei Zhang
Junmei Zhang
LWLin Wang
Lin Wang
MDMark K. Donnelly
Mark K. Donnelly
Lisa Cencia RohanLisa Cencia Rohan
Lisa Cencia Rohan
Background/Objectives: With the ongoing efforts in supporting the discovery of novel targeted drug delivery systems for the upper region of the female reproductive tract (FRT), it is imperative to understand the local drug disposition pathways. We aim to obtain a comprehensive profile of the drug transporters and drug-metabolizing enzymes in the human ectocervix, uterus, and fallopian tubes, as these factors may substantially influence mucosal penetration, tissue exposure, drug disposition, and the risk of drug–drug interactions. Methods: Gene expression of 12 drug transporters and 21 drug-metabolizing enzymes was quantified using RT-qPCR. Protein expression of highly expressed transporters was assessed using immunohistochemistry (IHC). Results: Among the 12 transporters analyzed, the efflux transporters P-gp, BCRP, and MRP4 exhibited the highest expression across the ectocervix, endometrium, myometrium, and fallopian tubes, with P-gp consistently showing the greatest abundance in all evaluated FRT tissues. Expression of these transporters was significantly higher (6–17×) in myometrium compared with ectocervix. IHC demonstrated strong localization of P-gp, BCRP, and MRP4 to epithelial layers facing the lumen, as well as to stromal and vascular endothelial cells. For drug-metabolizing enzymes, all 21 phase I and II enzymes were detectable across the FRT, and 15 were expressed at comparatively higher levels across all tissue types. These included CYP1A1, CYP1B1, CYP2B6, CYP2C8, CYP2C19, CYP3A4, UGT1A1, UGT1A3, UGT1A4, UGT1A7, UGT1A8, UGT1A10, UGT2B4, UGT2B15, and UGT2B17. Conclusions: The gene expression and localization data obtained from this work may improve our understanding of drug disposition in the FRT, which will inform selection, design, and optimization of drugs intended for targeted delivery within the FRT.